FMA
PGNX

FNY Managed Accounts’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

FNY Managed Accounts’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-42,000
Closed -$254K – 625
2015
Q1 		$251K Buy
+42,000
New +$264K 0.21% 65

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FNY Managed Accounts's PGNX Position: Q2 2015 in Review

FNY Managed Accounts sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2015, closing a stake of 42,000 shares — an estimated $254K sold.

FNY Managed Accounts first reported a position in PGNX in Q1 2015 and held it in 1 quarter. The position peaked at $251K in Q1 2015. 121 funds tracked by Wall St. Rank hold PGNX as of Q2 2015.

  • FNY Managed Accounts reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • FNY Managed Accounts sold 42,000 Progenics Pharmaceuticals Inc shares in Q2 2015, an estimated $254K.
  • FNY Managed Accounts first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 1 quarter.
  • FNY Managed Accounts's Progenics Pharmaceuticals Inc position peaked at $251K in Q1 2015.
  • 121 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2015.

Based on FNY Managed Accounts's 13F filing for Q2 2015, filed 30 Jul 2015.